Perjeta (pertuzumab)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.

Perjeta is a medicine that targets the HER2 receptor, which is designed specifically to prevent the HER2 receptor from pairing with other HER receptors on the surface of cancer cells. Binding of Perjeta to HER2 may also signal the body’s immune system to destroy the cancer cells. The mechanisms of action of Perjeta and Herceptin (trastuzumab) are believed to complement each other and provide a more comprehensive dual blockade of HER signaling pathways, thus preventing tumor cell growth and survival.1


In Bangladesh Perjeta is approved for the following indications.2

Metastatic Breast Cancer

Perjeta is indicated in combination with Herceptin and docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease


Early Breast Cancer

Perjeta is indicated in combination with Herceptin and chemotherapy for the:

  • neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (see Dosage and Administration and Clinical Studies).
  • adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (see 3.1.2 Clinical Studies)


For more disease and medicine related queries you may discuss with your physician.


In Bangladesh Perjeta is available as

Vials 420 mg/14 ml


Be sure to contact your doctor if you:

Are a woman who could become pregnant, or may be pregnant

  • If a patient becomes pregnant while receiving PERJETA and Herceptin, or within 7 months following the last dose of PERJETA and Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at

    +8801766686086 and/ or

    [email protected]

  • Additional information will be requested during a PERJETA and Herceptin-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of PERJETA and Herceptin and to provide appropriate information to health authorities, healthcare providers, and patients
  • For additional information, please refer to PERJETA Product Information and Herceptin Product Information

Winning the battle against breast cancer

Breast cancer is the leading cancer among all cancer types in women worldwide including Bangladesh. About 1 out of every 4 cancer patients in the world suffers from this cancer. However, the good news is, if the disease can be diagnosed at an early stage and proper treatment can be given it can be cured in 99% cases, which comes down to 27% for Advance Stage. Although most of the cancers are difficult to diagnose at an early stage, breast cancer is often more likely to be diagnosed early. All you need is the right information and awareness. You can diagnose the disease at an early stage through regular breast examinations (BSE).


1. Global Website: Products – Perjeta. [Internet; cited 2018, November 08]. Retrieved from

2. Perjeta Product Information _ BD Ro 436-8451 _ December 2020